Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer rash drug trial halted early – little known

NCT ID NCT04697069

Symptom relief Sponsor: Vanda Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, we cannot draw any reliable conclusions about whether the drug works or is safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Imsidolimab (ANB019), a humanized monoclonal antibody
What this could lead to
If it worked, this could point toward a treatment for the painful skin rash that some cancer patients get from their medications.
What could go wrong
The trial was terminated early with only 4 participants, so we have very little data. It is unclear if the drug is effective or safe for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

4 people

The number who actually took part.

Started

May 2021

Finished

Dec 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has cancer * Participant is treated with an oral or injectable Food and Drug Administration (FDA)-approved EGFRi or MEKi therapy * Participant has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per common terminology criteria for adverse events (CTCAE) version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1. Exclusion Criteria: * Participant has infected EGFRi/MEKi-associated acneiform rash according to investigator's evaluation. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acneiform eruptions are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acneiform dermatitis Acneiform Eruptions cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acneiform eruptions

Contacts and locations

Locations

  • Site 101

    St Louis, Missouri, 63110, United States

  • Site 102

    Tampa, Florida, 33620, United States

  • Site 103

    Houston, Texas, 77030, United States

  • Site 105

    Columbus, Ohio, 43215, United States

  • Site 106

    Boston, Massachusetts, 02215, United States

  • Site 201

    Szczecin, 70-784, Poland

  • Site 203

    Poznan, 60-569, Poland

  • Site 204

    Gliwice, 44-102, Poland

  • Site 301

    Olomouc, 779 00, Czechia

  • Site 302

    New Town, Praha 2, 128 00, Czechia

  • Site 303

    Brno, 656-91, Czechia

  • Site 304

    Plzen-Bory, 305 99, Czechia

  • Site 401

    Tbilisi, 0186, Georgia

  • Site 402

    Tbilisi, 0144, Georgia

  • Site 403

    Tbilisi, 0160, Georgia

  • Site 404

    Batumi, 6000, Georgia

  • Site 405

    Tbilisi, 0160, Georgia

  • Site 601

    Riga, 1038, Latvia

More trials for these conditions

Other studies related to the condition(s) this trial covers.